Transduction of the herpes thymidine kinase gene into premalignant murine mammary epithelial cells renders subsequent breast cancers responsive to ganciclovir therapy

Human Gene Therapy

Volumn 7, Issue 10, 1996, Pages 1197-1204

  Moolten, Frederick L ^a,b   Vonderhaar, Barbara K ^c   Mroz, Paula J ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER RISK; CONTROLLED STUDY; DRUG SENSITIVITY; EXPRESSION VECTOR; GENE THERAPY; GENETIC TRANSDUCTION; HERPES; MOUSE; NONHUMAN; PRECANCER; RETROVIRUS;

ANIMALIA; HERPES; MURINAE; UNIDENTIFIED RETROVIRUS;

EID: 0030036528     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.10-1197     Document Type: Article

References (31)

1. ANDERSON, W.F. (1994). Editorial: was it just stupid or are we poor educators? Hum. Gene Ther. 5, 791-792.
2. BECK, C., CAYEUX, S., LUPTON, S.D., DORKEN, B., and BLANKENSTEIN, T. (1995). The thymidine kinase/ganciclovir-mediated "suicide" effect is variable in different tumor cells. Hum. Gene Ther. 6, 1525-1530.
3. BENDER, M.A., PALMER, T.D., GELINAS, R.E., and MILLER, A.D. (1987). Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region. J. Virol. 61, 1639-1646.
4. BORDIGNON, C., and BONINI, C. (1995). Transfer of the HSV-TK gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum. Gene Ther. 6, 813-819.
5. CARUSO, M., PANIS, Y., GAGANDEEP, S., HOUSSIN, D., SALZMANN, J-L., and KLATZMANN, D. (1993). Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA 90, 7024-7028.
6. COLAK, A., GOODMAN, J.C., CHEN, S-H., WOO, S.L.C., GROSSMAN, R.G., and SHINE, H.D. (1995). Adenovirus-mediated gene therapy in an experimental model of breast cancer metastatic to the brain. Hum. Gene Ther. 6, 1317-1322.
7. CULVER, K.W., RAM, Z., WALLBRIDGE, S., ISHII, H., ODLFIELD, E.H., and BLAESE, R.M. (1992). In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors. Science 256, 1550-1552.
8. FEARON, E.R., HAMILTON, S.R., and VOGELSTEIN, B. (1987). Clonal analysis of human colorectal tumors. Science 238, 193-197.
9. FIALKOW, P.J. (1976). Clonal origin of human tumors. Biochim. Biophys. Acta 458, 283-321.
10. FREEMAN, S.M., ABBOUD, C.N., WHARTENBY, K.A., PACKMAN, C.H., KOEPLIN, D.S., MOOLTEN, F.L., and ABRAHAM, G.N. (1993). The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53, 5274-5283.
11. HARRIS, J.D., GUTIERREZ, A.A., HURST, H.C., SIKORA, K., and LEMOINE, N.R. (1994). Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther. 1, 170-175.
12. JERRY, D.J., OZBUN, M.A., KITTRELL, F.S., LANE, D.P., MEDINA, D., and BUTEL, J.S. (1993). Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development. Cancer Res. 53, 3374-3381.
13. KITTRELL, F.S., OBORN, C.J., and MEDINA, D. (1992). Development of mammary preneoplasias in vivo from mouse mammary epithelial cell lines in vitro. Cancer Res. 52, 1924-1932.
14. LINK, C.J., JR., KOLB, E.M., and MULDOON, R.R. (1995). Preliminary in vitro efficacy and toxicities studies of the herpes simplex thymidine kinase gene system for the treatment of breast cancer. Hybridoma 14, 143-147.
15. MANOME, Y., ABE, M., HAGEN, M.F., FINE, H.A., and KUFE, D.W. (1994). Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Res. 54, 5408-5413.
16. MARKOWITZ, D., GOFF, S., and BANK, A. (1988). A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 62, 1120-1124.
17. MOOLTEN, F.L. (1986). Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46, 5276-5281.
18. MOOLTEN, F.L. (1990). Mosaicism induced by gene insertion as a means of improving chemotherapeutic selectivity. Crit. Rev. Immunol. 10, 203-233.
19. MOOLTEN, F.L. (1994). Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther. 1, 279-287.
20. MOOLTEN, F.L., and CUPPLES, L.A. (1992). A model for predicting the risk of cancer consequent to retroviral gene therapy. Hum. Gene Ther. 3, 479-486.
21. MOOLTEN, F.L., and WELLS, J.M. (1990). Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 82, 297-300.
22. MOOLTEN, F.L., WELLS, J.M., HEYMAN, R.A., and EVAMS, R.M. (1990). Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum. Gene Ther. 1, 125-134.
23. MOOLTEN, F., WELLS, J.M., and MROZ, P.J. (1992). Multiple transduction as a means of preserving ganciclovir chemosensitivity in sarcoma cells carrying retrovirally transduced herpes thymidine kinase genes. Cancer Lett. 64, 257-263.
24. PALMER, T.D., ROSMAN, G.J., OSBORNE, W.R.A., and MILLER, A.D. (1991). Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc. Natl. Acad. Sci. USA 88, 1330-1334.
25. PETO, R., PIKE, M.C., ARMITAGE, P., BRESLOW, N.B., COX, D.R., HOWARD, S.V., MANTEL, N., McPHERSON, K., PETO, J., and SMITH, P.G. (1977). Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer 35, 1-39.
26. SACCO, M.G., MANGIARINI, L., VILLA, A., MACCHI, P., BARBIERI, O., SACCHI, M.C., MONTEGGIA, E., FASOLO, V., VEZZONI, P., and CLERICI, L. (1995). Local regression of breast tumors following intramammary ganciclovir administration in double transgenic mice expressing neu oncogene and herpes simplex virus thymidine kinase. Gene Ther. 2, 493-497.
27. TAPSCOTT, S.J., MILLER, A.D., OLSON, J.M., BERGER, M.S., GROUDINE, M., and SPENCE, A.M. (1994). Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc. Natl. Acad. Sci. USA 91, 8185-8189.
28. TIBERGHIEN, P., REYNOLDS, C.W., KELLER, J., SPENCE, S., DESCHASEAUX, M., CERTOUX, J.M., CONTASSOT, E., MURPHY, W.J., LYONS, R., CHIANG, Y., HERVE, P., LONGO, D.L., and RUSCETTI, F.W. (1994). Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 84, 1333-1341.
29. WANG, B., KENNAN, W.S., YASUKAWA-BARNES, J., LINDSTROM, M.J., and GOULD, M.N. (1991a). Carcinoma induction following direct in situ transfer of v-Ha-ras into rat mammary epithelial cells using replication-defective retrovirus vectors. Cancer Res. 51, 2642-2648.
30. WANG, B., KENNAN, W.S., YASUKAWA-BARNES, J., LINDSTROM, M.J., and GOULD, M.N. (1991b). Frequent induction of mammary carcinomas following neu oncogene transfer into in situ mammary epithelial cells of susceptible and resistant rat strains. Cancer Res. 51, 5549-5654.
31. ZWIEBEL, J.A., FREEMAN, S.M., and VONDERHAAR, B.K. (1990). In vivo retroviral transduction of mammary epithelium. Proc. Am. Assoc. for Cancer Res. 31, 212.